Biosim­u­la­tion out­fit nets $15M Se­ries A in push to make pre­clin­i­cal R&D more pre­dictable

VeriSIM Life has been work­ing on cre­at­ing a biosim­u­la­tion plat­form since its found­ing in 2017 — and af­ter more than four years and a pre-seed and seed round, the Cal­i­for­nia soft­ware firm now has a Se­ries A un­der its belt.

The $15 mil­lion round, led by Mor­pheus Ven­tures and sup­port­ed by new in­vestors De­bio­pharm In­no­va­tion Fund and Col­or­con Ven­tures, in­cludes ex­ist­ing in­vestors OCA Ven­tures, In­tel Cap­i­tal, Ser­ra Ven­tures and Susa Ven­tures. The round will fund VeriSIM Life for the next 2 to 2½ years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER